BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20575022)

  • 21. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
    Saini N; Ma J; Milton DR; Patel R; Varma A; Bashir Q; Delgado R; Mukherjee A; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Tang G; Mehta R; Srour S; Khouri IF; Iyer S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
    Clin Cancer Res; 2019 Nov; 25(22):6781-6787. PubMed ID: 31481508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 23. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical Analysis on the Therapeutic Efficacy of Autologous Hematopoietic Stem Cell Transplantation in 56 Multiple Myeloma Patients].
    Wang CY; Xia B; Ning QY; Tian C; Zhao HF; Yang HL; Li MZ; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1396-1402. PubMed ID: 30295257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
    Muta T; Miyamoto T; Fujisaki T; Ohno Y; Kamimura T; Kato K; Takenaka K; Iwasaki H; Eto T; Takamatsu Y; Teshima T; Akashi K;
    Intern Med; 2013; 52(1):63-70. PubMed ID: 23291675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.
    Chong YP; Kim S; Ko OB; Koo JE; Lee D; Park SH; Park SJ; Lee D; Kim SW; Suh C
    J Korean Med Sci; 2008 Oct; 23(5):819-24. PubMed ID: 18955788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
    Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
    Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.
    Kawamura K; Ikeda T; Hagiwara S; Mori T; Shinagawa A; Nishiwaki K; Ohashi K; Kubonishi S; Fukuda T; Ito T; Tomita N; Ichinohe T; Kato K; Morishima Y; Atsuta Y; Sunami K; Kanda Y
    Leuk Lymphoma; 2016 Sep; 57(9):2077-83. PubMed ID: 26961137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
    Cordas Dos Santos DM; Saliba RM; Patel R; Bashir Q; Saini N; Hosing C; Kebriaei P; Khouri IF; Nieto Y; Popat U; Ahmed H; Lee HC; Manasanch EE; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1077-1083. PubMed ID: 31786242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years.
    Bashir Q; Chamoun K; Milton DR; Khan M; Ahmed S; Mehta R; Popat UR; Kebriaei P; Nieto Y; Oran B; Ciurea SO; Hosing C; Khouri I; Patel K; Manasanch EE; Lee HC; Orlowski RZ; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2019 Dec; 60(14):3536-3543. PubMed ID: 31282244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.
    Shah N; Cornelison AM; Saliba R; Ahmed S; Nieto YL; Bashir Q; Parmar S; Hosing C; Popat U; Shpall EJ; Champlin RE; Qazilbash M
    Eur J Haematol; 2017 Dec; 99(6):532-535. PubMed ID: 28895206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
    Shah GL; Landau H; Londono D; Devlin SM; Kosuri S; Lesokhin AM; Lendvai N; Hassoun H; Chung DJ; Koehne G; Jhanwar SC; Landgren O; Levine R; Giralt SA
    Leuk Lymphoma; 2017 Aug; 58(8):1823-1831. PubMed ID: 28078910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
    Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.
    Bashir Q; Shah N; Parmar S; Wei W; Rondon G; Weber DM; Wang M; Orlowski RZ; Thomas SK; Shah J; Qureshi SR; Dinh YT; Popat U; Anderlini P; Hosing C; Giralt S; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2012 Jan; 53(1):118-22. PubMed ID: 21780997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
    Georges GE; Maris MB; Maloney DG; Sandmaier BM; Sorror ML; Shizuru JA; Lange T; Agura ED; Bruno B; McSweeney PA; Pulsipher MA; Chauncey TR; Mielcarek M; Storer BE; Storb R
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):423-32. PubMed ID: 17287157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
    Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.